• A number of risk factors have been proposed for the development of neuroleptic malignant syndrome, but these have not been subjected to controlled study. To address this problem, we performed a case-control study comparing 18 patients with neuroleptic malignant syndrome and 36 matched neuroleptictreated control patients with no known history of the syndrome to identify potential risk factors. Patients with neuroleptic malignant syndrome displayed significantly greater psychomotor agitation, received significantly higher doses of neuroleptics at greater rates of dosage increase, and received a greater number of intramuscular injections than controls.
Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA. Risk Factors for Neuroleptic Malignant Syndrome: A Case-Control Study. Arch Gen Psychiatry. 1989;46(10):914–918. doi:10.1001/archpsyc.1989.01810100056011
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: